Search VTRS
Viatris Inc
Nasdaq · CIK 1792044
Last close17.6
Daily change+0.14 (0.80%)
10 Years gain-47.09%
Dividends TTM0.48 (+0.00%)
Dividend yield2.75%
Fundamental Analysis
VTRS · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
11.6Momentum
100.0Acceleration
100.0Confidence
76.0Annual Revenue9
Quarterly Revenue30
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.4 / 25
Quality5.5 / 25
Capital Efficiency0.6 / 20
Balance Sheet4.5 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 20.9921 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 2.4405%.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.1288 percentage points.
Low interest coverage · HIGHInterest coverage is 0.7094x.
Key Metrics
Revenue Growth TTM1.05%OK
Revenue CAGR 3Y-4.22%OK
Gross Margin36.5%OK
Operating Margin2.32%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC0.96%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-2.44%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $14.25B | $5.01B | -$2.66B | $2.32B | $1.94B | 35.18% | -18.69% | 13.59% | -7.05% | n/a |
| 2025 FY Dec 31, 2024 | $14.69B | $5.62B | $10.10M | $2.30B | $1.98B | 38.27% | 0.07% | 13.45% | 0.02% | n/a |
| 2025 FY Dec 31, 2023 | $15.39B | $6.44B | $766.20M | $2.90B | $2.52B | 41.84% | 4.98% | 16.4% | 1.3% | 1.21B |
| 2024 FY Dec 31, 2022 | $16.22B | $6.50B | $1.61B | $3.00B | $2.59B | 40.06% | 9.96% | 15.99% | 2.97% | 1.22B |
| 2023 FY Dec 31, 2021 | $17.81B | $5.58B | -$34.00M | $3.02B | $2.56B | 31.3% | -0.19% | 14.37% | -0.06% | 1.21B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $14.57B | sum latest 4 fiscal quarters Revenue | OK | 0001792044-26-000041, 0001792044-25-000046 |
| Revenue Growth TTM | 1.05% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001792044-26-000041, 0001792044-25-000046 |
| Revenue CAGR 3Y | -4.22% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001792044-26-000013 |
| Revenue CAGR 5Y | 3.81% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001792044-26-000013 |
| Gross Profit CAGR 3Y | -8.28% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001792044-26-000013 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001792044-26-000041, 0001792044-25-000046 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 36.5% | Gross Profit / Revenue | OK | 0001792044-26-000041, 0001792044-25-000046 |
| Operating Margin | 2.32% | Operating Income / Revenue | OK | 0001792044-26-000041, 0001792044-25-000046 |
| ROIC | 0.96% | NOPAT / Average Invested Capital | OK | 0001792044-26-000041, 0001792044-25-000046 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001792044-26-000041 |
| Interest Coverage | 0.71x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 1.58x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.07x | (Cash + Short-term Investments) / Total Debt | OK | 0001792044-26-000041 |